4.4 Article

HS-1793 inhibits cell proliferation in lung cancer by interfering with the interaction between p53 and MDM2

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, Research & Experimental

Molecular Pathology of Lung Cancer

James J. Saller et al.

Summary: This article provides an overview of the molecular pathology of lung cancer, including the most significant molecular alterations of the genome, transcriptome, and epigenome. It discusses the insights gained from the use of next-generation sequencing (NGS) in lung cancer research and explores concepts such as intertumor heterogeneity, intratumor heterogeneity, tumor mutational burden, and liquid biopsy. Additionally, it highlights the importance of molecular pathology in refining the understanding of histologic phenotypes of non-small-cell lung cancer (NSCLC) and the biology of small-cell lung cancer.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2022)

Review Biochemistry & Molecular Biology

Of the many cellular responses activated by TP53, which ones are critical for tumour suppression?

Annabella F. Thomas et al.

Summary: TP53 is a crucial tumor suppressor that regulates various cellular processes to prevent tumorigenesis, including cell death, cell cycle, cell senescence, DNA repair, and metabolism. Mutations in the TP53 gene are commonly found in human cancers and are associated with poor responses to therapy. However, the mechanism by which TP53 suppresses tumors involves more than just inducing apoptotic cell death, as mice lacking critical effectors of TP53-induced apoptosis or cell cycle arrest and senescence do not spontaneously develop tumors.

CELL DEATH AND DIFFERENTIATION (2022)

Review Pharmacology & Pharmacy

Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer

James Isaacs et al.

Summary: Approximately one-third of NSCLC patients can undergo surgical resection. Neoadjuvant and adjuvant chemotherapy have been shown to improve survival outcomes. Recent trials have explored immunotherapy and targeted therapy in early-stage patients, showing improved disease-free survival.
Article Chemistry, Medicinal

Small-molecule MDM2 inhibitors in clinical trials for cancer therapy

Shuai Wang et al.

Summary: Inhibition of the MDM2-p53 protein-protein interaction using small-molecule inhibitors is a promising strategy for cancer therapy. Many highly potent and selective small-molecule MDM2 inhibitors have been discovered and are currently undergoing different clinical trials. This review provides an overview of the function of MDM2 and the identification, optimization, preclinical, and clinical studies of clinical-stage MDM2 inhibitors. It also discusses challenges, potential toxicity, and future perspectives, which will guide the design of new small-molecule MDM2 inhibitors.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Review Ophthalmology

The roles of mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A review

Heng Jiang et al.

Summary: Mouse double minute 2 (MDM2) plays an important role in regulating the level of p53 and is associated with various ocular disorders. Anti-MDM2 therapy shows promise in treating these diseases.

EXPERIMENTAL EYE RESEARCH (2022)

Review Biochemistry & Molecular Biology

Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death

Nayeong Koo et al.

Summary: p53 is a tumor suppressor that regulates cell function through various mechanisms. Researchers aim to reactivate p53 and induce cancer cell death by developing drugs that target the p53-MDM2 interaction, and have identified potential antagonists.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Review Medicine, General & Internal

Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management

Fabrizio Tabbo et al.

Summary: The treatment landscape of advanced non-small cell lung cancer (NSCLC) has significantly improved in the past decade with the introduction of tyrosine kinase inhibitors (TKIs) targeting oncogenic drivers such as anaplastic lymphoma kinase (ALK) translocations. Among these TKIs, brigatinib, a second-generation (2G) inhibitor, has shown notable activity in ALK+ NSCLC patients, including those with central nervous system (CNS) disease, and has a good safety profile. However, the abundance of therapeutic options for these patients poses challenges in determining the best approach and administration sequence. In this review, we summarized the efficacy, pharmacological and safety profile of brigatinib, as well as its potential applications in other contexts.

MINERVA MEDICA (2022)

Review Surgery

Lung Metastases: Current Surgical Indications and New Perspectives

Giuseppe Mangiameli et al.

Summary: Pulmonary metastasectomy is an established treatment option for patients with lung metastases, providing improved long-term survival. This mini-review discusses the current state and future perspectives of thoracic surgery in the surgical management of lung metastases, emphasizing the principles of surgical therapy and reporting on surgical indications and oncological results.

FRONTIERS IN SURGERY (2022)

Review Biochemistry & Molecular Biology

Resveratrol and Prostate Cancer: The Power of Phytochemicals

Nadia Zaffaroni et al.

Summary: Prostate cancer is the fifth leading cause of tumor-related deaths in men globally, with its long latency period making it ideal for chemopreventive studies. Resveratrol, a natural compound, has shown promise as a chemopreventive agent and enhancer of antitumor activity in prostate cancer. Ongoing clinical trials are exploring the potential of resveratrol as an antimetastatic agent in prostate cancer treatment.

CURRENT MEDICINAL CHEMISTRY (2021)

Article Multidisciplinary Sciences

Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis

Loretah Chibaya et al.

Summary: The phosphorylation of Mdm2 by Akt was found to reduce p53 levels and prevent senescence in cells exposed to oxidative stress. This resulted in the promotion of lung cancers driven by Kras(G12D) and carcinogen-induced papilloma and hepatocellular carcinomas in mouse models of ROS-induced cancer. These findings highlight a unique physiological role for Akt-Mdm2-p53 signaling in regulating cell growth and tumorigenesis in response to oxidative stress.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Review Cell Biology

The roles and regulation of MDM2 and MDMX: it is not just about p53

Alyssa M. Klein et al.

Summary: MDM2 and MDMX, well-known as proteins that restrain the p53 tumor suppressor protein, have diverse functions in cells and are regulated at multiple levels including transcription and protein modification. Both proteins may contribute to oncogenic transformation while also potentially playing a tumor suppressive role in certain contexts. Understanding how various small molecules affecting MDM2 and MDMX may impact their p53-independent activities is crucial due to their therapeutic potential.

GENES & DEVELOPMENT (2021)

Article Oncology

Germacrone induces lung cancer cell apoptosis and cell cycle arrest via the Akt/MDM2/p53 signaling pathway

Yang Zhao et al.

Summary: This study showed that Germacrone inhibited lung cancer cell proliferation, induced cell apoptosis and G(1)/S cell cycle arrest. Germacrone also altered the expression levels of Akt/MDM2/p53 signaling pathway-related proteins. Administering Akt activator SC79 reversed the effects of Germacrone in lung cancer cells.

MOLECULAR MEDICINE REPORTS (2021)

Review Toxicology

The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment

Natalie Silk et al.

Summary: Prostate cancer is a common cancer in men, particularly in those over 65, making it a significant burden in the future. Recent research has emphasized the role of the tumor microenvironment in cancer development, with natural products like resveratrol showing promise in targeting the TME to inhibit prostate cancer progression.

JOURNAL OF XENOBIOTICS (2021)

Article Pharmacology & Pharmacy

Sesamin suppresses NSCLC cell proliferation and induces apoptosis via Akt/p53 pathway

Yueming Chen et al.

TOXICOLOGY AND APPLIED PHARMACOLOGY (2020)

Review Biochemistry & Molecular Biology

Potential Adverse Effects of Resveratrol: A Literature Review

Abdullah Shaito et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Article Medicine, Research & Experimental

Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt/NF-κB signaling

Mohammad Rasheduzzaman et al.

LIFE SCIENCES (2018)

Review Multidisciplinary Sciences

The biology and management of non-small cell lung cancer

Roy S. Herbst et al.

NATURE (2018)

Review Biochemistry & Molecular Biology

How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?

Brandon J. Aubrey et al.

CELL DEATH AND DIFFERENTIATION (2018)

Review Food Science & Technology

Resveratrol as MDR reversion molecule in breast cancer: An overview

Nafiseh Sadat Alamolhodaei et al.

FOOD AND CHEMICAL TOXICOLOGY (2017)

Article Pharmacology & Pharmacy

Resveratrol raises in vitro anticancer effects of paclitaxel in NSCLC cell line A549 through COX-2 expression

Fanhua Kong et al.

KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY (2017)

Review Oncology

Non-small cell lung cancer: current treatment and future advances

Cecilia Zappa et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2016)

Article Medicine, General & Internal

Non-small-cell lung cancer

Cesare Gridelli et al.

NATURE REVIEWS DISEASE PRIMERS (2015)

Article Toxicology

In Vitro Genotoxicity Assessment of a Novel Resveratrol Analogue, HS-1793

Min Ho Jeong et al.

TOXICOLOGICAL RESEARCH (2014)

Article Biochemistry & Molecular Biology

Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions

A. R. Neves et al.

CURRENT MEDICINAL CHEMISTRY (2012)

Review Pharmacology & Pharmacy

Pharmacological Activation of p53 in Cancer Cells

Mohammad Athar et al.

CURRENT PHARMACEUTICAL DESIGN (2011)

Article Oncology

Role of p53 in Cell Death and Human Cancers

Toshinori Ozaki et al.

Cancers (2011)

Article Pharmacology & Pharmacy

Effectiveness and Safety of Bevacizumab for Unresectable Non-Small-Cell Lung Cancer A Meta-Analysis

Kun Yang et al.

CLINICAL DRUG INVESTIGATION (2010)

Article Dermatology

Resveratrol regulates p66Shc activation in HaCaT cells

Gabriella Fabbrocini et al.

EXPERIMENTAL DERMATOLOGY (2010)

Article Pharmacology & Pharmacy

A novel resveratrol derivative, HS1793, overcomes the resistance conferred by Bcl-2 in human leukemic U937 cells

Seung Hun Jeong et al.

BIOCHEMICAL PHARMACOLOGY (2009)

Review Biotechnology & Applied Microbiology

Resveratrol and its analogs: Defense against cancer, coronary disease and neurodegenerative maladies or just a fad?

Philipp Saiko et al.

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2008)

Article Oncology

Identifying the estrogen receptor coactivator PELP1 in autophagosomes

Kazufumi Ohshiro et al.

CANCER RESEARCH (2007)

Article Oncology

Focus on lung cancer

JD Minna et al.

CANCER CELL (2002)

Review Medicine, General & Internal

Lung cancer

PC Hoffman et al.

LANCET (2000)